
Sign up to save your podcasts
Or


Dr. Monty Pal shares highlights from Day 3 of the 2026 ASCO Annual Meeting, including new research for the treatment of advanced CRC and mCRPC, TIL cell therapy in advanced non-uveal melanoma, and an ultra-low dose immunotherapy trial in head and neck squamous cell carcinoma.
LINK TO FULL TRANSCRIPT
By American Society of Clinical Oncology (ASCO)4.6
5656 ratings
Dr. Monty Pal shares highlights from Day 3 of the 2026 ASCO Annual Meeting, including new research for the treatment of advanced CRC and mCRPC, TIL cell therapy in advanced non-uveal melanoma, and an ultra-low dose immunotherapy trial in head and neck squamous cell carcinoma.
LINK TO FULL TRANSCRIPT

319 Listeners

506 Listeners

40 Listeners

65 Listeners

766 Listeners

122 Listeners

2,237 Listeners

821 Listeners

188 Listeners

47 Listeners

31 Listeners

837 Listeners

59 Listeners

195 Listeners

46 Listeners